US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical.
CN201 has potential applications in B-cell malignancies and autoimmune diseases.
CN201 is currently being studied in clinical trials for the treatment of non-Hodgkin's lymphoma and B-cell acute lymphocytic leukaemia. Preliminary data suggest that it is well-tolerated and may lead to significant reductions in B-cell populations.
Merck acquired full global rights to CN201 for approximately USD750m. This acquisition strengthens Merck's pipeline of potential treatments for B-cell associated diseases.
Devonian files patent for Thykamine as antifibrotic agent
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
AbbVie completes Nimble Therapeutics acquisition
Johnson & Johnson reports nipocalimab Phase 3 study results published in The Lancet Neurology
Diamyd Medical granted South Korean patent for insulin antigen treatment
Johnson & Johnson granted Priority Review for nipocalimab in gMG
Hemogenyx Pharmaceuticals raises GBP340,000 for AML clinical trials
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Breckenridge Pharmaceutical launches FDA approved methadone injection